Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments. [electronic resource]
Producer: 20120213Description: 1612-8 p. digitalISSN:- 1440-1746
- Antineoplastic Agents -- adverse effects
- Benzenesulfonates -- adverse effects
- Carcinoma, Hepatocellular -- blood
- Chi-Square Distribution
- Female
- Humans
- Kaplan-Meier Estimate
- Liver Neoplasms -- blood
- Logistic Models
- Male
- Middle Aged
- Neoplasm Invasiveness
- Niacinamide -- analogs & derivatives
- Patient Selection
- Phenylurea Compounds
- Propensity Score
- Proportional Hazards Models
- Protein Kinase Inhibitors -- adverse effects
- Pyridines -- adverse effects
- Republic of Korea
- Retrospective Studies
- Risk Assessment
- Risk Factors
- Sorafenib
- Survival Rate
- Time Factors
- Treatment Outcome
- alpha-Fetoproteins -- analysis
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.